pCVL SFFV d14GFP EF1s HA.NLS.Sce(opt) Citations (9)

Originally described in: Tracking genome engineering outcome at individual DNA breakpoints.
Certo MT, Ryu BY, Annis JE, Garibov M, Jarjour J, Rawlings DJ, Scharenberg AM Nat Methods. 2011 Jul 10;8(8):671-6. doi: 10.1038/nmeth.1648. PubMed Journal

---

Articles Citing pCVL SFFV d14GFP EF1s HA.NLS.Sce(opt)

Articles
Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination. Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzerini-Denchi E, Sfeir A. Nature. 2015 Feb 12;518(7538):254-7. doi: 10.1038/nature14157. Epub 2015 Feb 2. PubMed Associated Plasmids pX330(puro) Rosa26-H3F3B pcDNA 3.1(Hygro) myc-hPolQ-Flag
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Rasmussen RD, Gajjar MK, Jensen KE, Hamerlik P. Mol Oncol. 2016 Jan 8. pii: S1574-7891(16)00002-8. doi: 10.1016/j.molonc.2015.12.014. PubMed
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. Chroma K, Mistrik M, Moudry P, Gursky J, Liptay M, Strauss R, Skrott Z, Vrtel R, Bartkova J, Kramara J, Bartek J. Oncogene. 2016 Nov 14. doi: 10.1038/onc.2016.392. PubMed
Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity. Ohba S, Johannessen TA, Chatla K, Yang X, Pieper RO, Mukherjee J. Cell Rep. 2020 Apr 14;31(2):107518. doi: 10.1016/j.celrep.2020.03.082. PubMed
A multiplexed bioluminescent reporter for sensitive and non-invasive tracking of DNA double strand break repair dynamics in vitro and in vivo. Chien JC, Tabet E, Pinkham K, da Hora CC, Chang JC, Lin S, Badr CE, Lai CP. Nucleic Acids Res. 2020 Aug 14. pii: 5892751. doi: 10.1093/nar/gkaa669. PubMed Associated Plasmids pLenti-BLRR pLenti-trGluc pX330-gRNA
Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. Mehibel M, Xu Y, Li CG, Moon EJ, Thakkar KN, Diep AN, Kim RK, Bloomstein JD, Xiao Y, Bacal J, Saldivar JC, Le QT, Cimprich KA, Rankin EB, Giaccia AJ. J Clin Invest. 2021 Jun 1;131(11). pii: e146256. doi: 10.1172/JCI146256. PubMed
Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10. Mowat C, Mosley SR, Namdar A, Schiller D, Baker K. J Exp Med. 2021 Sep 6;218(9). pii: 212506. doi: 10.1084/jem.20210108. Epub 2021 Jul 23. PubMed
RHINO restricts MMEJ activity to mitosis. Brambati A, Sacco O, Porcella S, Heyza J, Kareh M, Schmidt JC, Sfeir A. bioRxiv. 2023 Mar 16:2023.03.16.532763. doi: 10.1101/2023.03.16.532763. Preprint. PubMed
DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors. Folly-Kossi H, Graves JD, Garan LAW, Lin FT, Lin WC. Cancer Res Commun. 2023 Oct 16;3(10):2096-2112. doi: 10.1158/2767-9764.CRC-23-0166. PubMed

If you have published an article using this material, please email us at to have your article added to this page.